Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage.
Greene
D A
DA
Department of Internal Medicine, University of Michigan, Ann Arbor.
Sima
A A
AA
Stevens
M J
MJ
Feldman
E L
EL
Killen
P D
PD
Henry
D N
DN
Thomas
T
T
Dananberg
J
J
Lattimer
S A
SA
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006943:Hyperglycemia / Q000503:physiopathology; D007294:Inositol / Q000378:metabolism; D007511:Ischemia; D009431:Neural Conduction / Q000502:physiology; D010525:Peripheral Nerves / Q000098:blood supply / Q000503:physiopathology; D010716:Phosphatidylinositols / Q000378:metabolism; D012377:Rodentia; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism
D010716:Phosphatidylinositols; D007294:Inositol; D000449:Aldehyde Reductase; D000254:Sodium-Potassium-Exchanging ATPase